Desloratadine-d4 (CAS 381727-29-3)

Desloratadine-d4 (DL-d4) is a significant compound in the field of allergy, asthma, and immunology, classified as a nonsedating-type labeled histamine H1-receptor antagonist. It serves as an actively labeled metabolite of Loratadine, exhibiting the ability to inhibit the generation and release of inflammatory mediators from basophils and mast cells. DL-d4, a synthetic derivative of desloratadine, acts as a labeled analog with a deuterium atom replacing a hydrogen atom at the 4th position. It finds diverse applications in scientific research, including the exploration of desloratadine′s mechanism of action, its biochemical and physiological effects, and laboratory experiments. Moreover, DL-d4 has been employed in laboratory studies focused on understanding the pharmacokinetics and pharmacodynamics of desloratadine. Mechanistically, Desloratadine-d4 operates similarly to desloratadine as an antagonist of the histamine H1 receptor, a G-protein coupled receptor. By binding to the receptor, Desloratadine-d4 effectively obstructs histamine binding, preventing its stimulation of the receptor. Consequently, this inhibition leads to the suppression of inflammatory mediators′ release, including leukotrienes and prostaglandins that play roles in allergic responses. Notably, Desloratadine-d4 has demonstrated efficacy in reducing symptoms associated with allergic rhinitis, such as sneezing, itching, and a runny nose. Additionally, it has been proven effective in alleviating symptoms of asthma, including wheezing and shortness of breath.